Correlation between a 2-week change in platelet count and clinical outcomes after the initiation of ravulizumab treatment in adult patients with atypical hemolytic uremic syndrome: post-hoc analysis of the phase III trial
This study was performed as a post-hoc analysis of the ALXN1210-aHUS-311 phase III clinical trial (NCT02949128, registered October 25, 2016).
Authors
- Jun Yokosawa
- Akihiko Shimono
- Shoichi Maruyama (ORCID: https://orcid.org/0000-0002-8858-632X)
- Masanori Matsumoto (ORCID: https://orcid.org/0000-0002-7243-3126)
- Keiichiro Hirose
- Edward Wang (ORCID: https://orcid.org/0000-0003-0810-7761)
Institutions
- Nagoya University Hospital (JP)
- Alexion Pharmaceuticals (United States) (US)
- Alexion Pharma (Switzerland) (CH)
- Nagoya University (JP)
- Nara Medical University (JP)
Publication Details
- Journal
- Thrombosis Journal
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1186/s12959-024-00652-1
- Citations
- 3
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- AstraZeneca
- Alexion Pharmaceuticals